US 12,123,019 B2
Uses of kinase inhibitors for inducing and maintaining pluripotency
Thorold W Theunissen, Belmont, MA (US); Nathanael S. Gray, Boston, MA (US); and Rudolf Jaenisch, Brookline, MA (US)
Assigned to Whitehead Institute for Biomedical Research, Cambridge, MA (US); and Dana-Farber Cancer Institute, Inc., Boston, MA (US)
Filed by Whitehead Institute for Biomedical Research, Cambridge, MA (US); and Dana-Farber Cancer Institute, Inc., Boston, MA (US)
Filed on Oct. 15, 2020, as Appl. No. 17/071,627.
Application 17/071,627 is a continuation of application No. 15/318,533, abandoned, previously published as PCT/US2015/036692, filed on Jun. 19, 2015.
Claims priority of provisional application 62/045,337, filed on Sep. 3, 2014.
Claims priority of provisional application 62/014,674, filed on Jun. 19, 2014.
Prior Publication US 2021/0230538 A1, Jul. 29, 2021
Int. Cl. C12N 5/0735 (2010.01); C12N 5/074 (2010.01)
CPC C12N 5/0606 (2013.01) [C12N 5/0696 (2013.01); C12N 2501/11 (2013.01); C12N 2501/115 (2013.01); C12N 2501/165 (2013.01); C12N 2501/727 (2013.01); C12N 2501/999 (2013.01)] 7 Claims
 
1. A method for changing the pluripotency state of a human cell to a more naïve state, the method comprising:
culturing a pluripotent human stem cell in a medium comprising N2B27 supplemented with:

OG Complex Work Unit Chemistry
(vi) 20 ng/mL Activin A, and
(vii) 20 ng/mL recombinant human leukemia inhibitory factor; and
maintaining the cell in culture under conditions suitable and a time sufficient to convert the pluripotency state of the cell to a more naïve state, wherein the more naïve state cell (i) exhibits OCT4 distal enhancer activity, (ii) upregulates TFCP2L1, REX1, and STELLA, and/or (iii) downregulates OTX2 and ZIC2/3 when compared to before the pluripotent stem cell is cultured in the medium.